2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/2iy5wruuedsh6.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/00yc7rcvua6a7.js","/_next/static/immutable/chunks/37ktb71aq3480.js","/_next/static/immutable/chunks/2d50b-7eu4558.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/2d6noqpp6ehas.js","/_next/static/immutable/chunks/1sx186c93bpzg.js","/_next/static/immutable/chunks/3dc-1n866s65i.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2w1bvggzb0ga8.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T4f0,A total of 139 participants were included in this analysis. ICGA-confirmed PCV was present in 44 participants in the treatment group receiving aflibercept, 8 mg, every 12 weeks (mean [SD] age, 72.2 [8.1] years; 50% male), 41 participants receiving 8 mg every 16 weeks (mean [SD] age, 73.2 [8.7] years; 63% male), and 54 participants receiving 2 mg every 8 weeks (mean [SD] age, 72.6 [8.2] years; 69% male). Mean baseline BCVA letter score (approximate Snellen) was 56.3 (20/80), 60.1 (20/63), and 57.6 (20/80), respectively, with 41, 37, and 51 participants completing week 48 and receiving a mean (SD) of 6.1 (0.4), 5.1 (0.5), and 7.0 (0.2) injections, including 68 of 78 (87%) treated with aflibercept, 8 mg, who maintained dosing intervals of 12 weeks or longer. In the treatment arms receiving aflibercept, 8 mg, every 12 and 16 weeks and aflibercept, 2 mg, every 8 weeks, LS mean BCVA change from baseline at week 48 was +9.5, +8.4, and +9.1 letters, respectively (estimated difference, 0.40; 95% CI, -4.4 to 5.2 letters for 8 mg every 12 weeks vs 2 mg every 8 weeks; -0.7; 95% CI, -4.6 to 3.2 letters for 8 mg every 16 weeks vs 2 mg every 8 weeks), and polypoidal lesions were absent in 37%, 47%, and 38% of participants, respectively, who completed week 48.31:Tc1c,In the Study of the Effects of High-Dose Aflibercept Injected Into the Eye of Patients With an Age-Related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye (PULSAR) phase 3 randomized clinical trial, treatment with aflibercept, 8 mg, demonstrated noninferior (4-letter margin) best-corrected visual acuity (BCVA) gains vs aflibercept, 2 mg, in participants with neovascular age-related macular degeneration (nAMD). This post hoc subgroup analysis evaluated clinical outcomes in participants with polypoidal choroidal vasculopathy (PCV). To compare the efficacy and safety of aflibercept, 8 mg vs 2 mg, monotherapy among participants with PCV in the PULSAR trial. This was a post hoc subgroup analysis of the PULSAR randomized clinical trial. The setting included hospitals and clinics in 12 countries where indocyanine green angiography (ICGA) was performed to identify PCV. Included were a subgroup of adults with nAMD enrolled in the PULSAR trial with ICGA-confirmed PCV. Study data were analyzed from August 2020 to July 2022. Participants were randomly assigned 1:1:1 to aflibercept, 8 mg, every 12 weeks or 16 weeks, or aflibercept, 2 mg, every 8 weeks, each after 3 initial monthly doses. From week 16, dosing intervals in the treatment arms receiving 8 mg every 12 weeks and every 16 weeks were shortened if predefined disease activity criteria were met at prespecified visits. Least-squares (LS) mean change in BCVA from baseline at week 48. A total of 139 participants were included in this analysis. ICGA-confirmed PCV was present in 44 participants in the treatment group receiving aflibercept, 8 mg, every 12 weeks (mean [SD] age, 72.2 [8.1] years; 50% male), 41 participants receiving 8 mg every 16 weeks (mean [SD] age, 73.2 [8.7] years; 63% male), and 54 participants receiving 2 mg every 8 weeks (mean [SD] age, 72.6 [8.2] years; 69% male). Mean baseline BCVA letter score (approximate Snellen) was 56.3 (20/80), 60.1 (20/63), and 57.6 (20/80), respectively, with 41, 37, and 51 participants completing week 48 and receiving a mean (SD) of 6.1 (0.4), 5.1 (0.5), and 7.0 (0.2) injections, including 68 of 78 (87%) treated with aflibercept, 8 mg, who maintained dosing intervals of 12 weeks or longer. In the treatment arms receiving aflibercept, 8 mg, every 12 and 16 weeks and aflibercept, 2 mg, every 8 weeks, LS mean BCVA change from baseline at week 48 was +9.5, +8.4, and +9.1 letters, respectively (estimated difference, 0.40; 95% CI, -4.4 to 5.2 letters for 8 mg every 12 weeks vs 2 mg every 8 weeks; -0.7; 95% CI, -4.6 to 3.2 letters for 8 mg every 16 weeks vs 2 mg every 8 weeks), and polypoidal lesions were absent in 37%, 47%, and 38% of participants, respectively, who completed week 48. Results of this post hoc analysis of the PULSAR randomized clinical trial in participants with PCV demonstrated similar visual and anatomic outcomes with aflibercept, 8 mg vs 2 mg, as administered in this trial, supporting the use of aflibercept, 8 mg, as an alternative monotherapy for PCV. ClinicalTrials.gov Identifier: NCT04423718.32:T11e7, Importance In the Study of the Effects of High-Dose Aflibercept Injected Into the Eye of Patients With an Age-Related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye (PULSAR) phase 3 randomized clinical trial, treatment with aflibercept, 8 mg, demonstrated noninferior (4-letter margin) best-corrected visual acuity (BCVA) gains vs aflibercept, 2 mg, in participants with neovascular age-related macular degeneration (nAMD). This post hoc subgroup analysis evaluated clinical outcomes in participants with polypoidal choroidal vasculopathy (PCV). Objective To compare the efficacy and safety of aflibercept, 8 mg vs 2 mg, monotherapy among participants with PCV in the PULSAR trial. Design, Setting, and Participants This was a post hoc subgroup analysis of the PULSAR randomized clinical trial. The setting included hospitals and clinics in 12 countries where indocyanine green angiography (ICGA) was performed to identify PCV. Included were a subgroup of adults with nAMD enrolled in the PULSAR trial with ICGA-confirmed PCV. Study data were analyzed from August 2020 to July 2022. Interventions Participants were randomly assigned 1:1:1 to aflibercept, 8 mg, every 12 weeks or 16 weeks, or aflibercept, 2 mg, every 8 weeks, each after 3 initial monthly doses. From week 16, dosing intervals in the treatment arms receiving 8 mg every 12 weeks and every 16 weeks were shortened if predefined disease activity criteria were met at prespecified visits. Main Outcomes and Measures Least-squares (LS) mean change in BCVA from baseline at week 48. Results A total of 139 participants were included in this analysis. ICGA-confirmed PCV was present in 44 participants in the treatment group receiving aflibercept, 8 mg, every 12 weeks (mean [SD] age, 72.2 [8.1] years; 50% male), 41 participants receiving 8 mg every 16 weeks (mean [SD] age, 73.2 [8.7] years; 63% male), and 54 participants receiving 2 mg every 8 weeks (mean [SD] age, 72.6 [8.2] years; 69% male). Mean baseline BCVA letter score (approximate Snellen) was 56.3 (20/80), 60.1 (20/63), and 57.6 (20/80), respectively, with 41, 37, and 51 participants completing week 48 and receiving a mean (SD) of 6.1 (0.4), 5.1 (0.5), and 7.0 (0.2) injections, including 68 of 78 (87%) treated with aflibercept, 8 mg, who maintained dosing intervals of 12 weeks or longer. In the treatment arms receiving aflibercept, 8 mg, every 12 and 16 weeks and aflibercept, 2 mg, every 8 weeks, LS mean BCVA change from baseline at week 48 was +9.5, +8.4, and +9.1 letters, respectively (estimated difference, 0.40; 95% CI, −4.4 to 5.2 letters for 8 mg every 12 weeks vs 2 mg every 8 weeks; −0.7; 95% CI, −4.6 to 3.2 letters for 8 mg every 16 weeks vs 2 mg every 8 weeks), and polypoidal lesions were absent in 37%, 47%, and 38% of participants, respectively, who completed week 48. Conclusions and Relevance Results of this post hoc analysis of the PULSAR randomized clinical trial in participants with PCV demonstrated similar visual and anatomic outcomes with aflibercept, 8 mg vs 2 mg, as administered in this trial, supporting the use of aflibercept, 8 mg, as an alternative monotherapy for PCV. Trial Registration ClinicalTrials.gov Identifier: NCT04423718 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"aflibercept: generic Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on aflibercept (generic). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/generic/aflibercept\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Generics\",\"item\":\"https://www.reachrx.ai/hub/tag/generic\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"aflibercept\",\"item\":\"https://www.reachrx.ai/hub/tag/generic/aflibercept\"}]}}"}}]],["$","$L2f",null,{"title":"aflibercept: Research & Clinical Takeaways","description":"Explore research on aflibercept (generic) — efficacy, safety, and comparative data.","papers":[{"doi":"10.1038/s41433-026-04710-y","pmid":"42552408","title":"Real-world comparative effectiveness of faricimab versus aflibercept 2 mg in treatment-naïve exudative neovascular AMD patients treated with a treat-and-extend regimen","journal_title":"Eye","journal_issn":"0950-222X","published_at":"2026-08-04T00:00:00.000Z","url":"https://doi.org/10.1038/s41433-026-04710-y","source_score":3,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-07T13:23:02.706Z","updated_at":"2026-08-07T13:23:02.706Z","tags":[{"paper_doi":"10.1038/s41433-026-04710-y","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04710-y","tag_type":"brand","value":"Eylea","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04710-y","tag_type":"brand","value":"Vabysmo","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04710-y","tag_type":"category","value":"Ophthalmology","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04710-y","tag_type":"condition","value":"Neovascular Age-Related Macular Degeneration","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04710-y","tag_type":"generic","value":"aflibercept","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04710-y","tag_type":"generic","value":"faricimab","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04710-y","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04710-y","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04710-y","tag_type":"modality","value":"Anti-VEGF Intravitreal Injection","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04710-y","tag_type":"modality","value":"Bispecific Antibody","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04710-y","tag_type":"sample_size","value":"n=172","value_numeric":172},{"paper_doi":"10.1038/s41433-026-04710-y","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04710-y","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04710-y","tag_type":"warning","value":"IPTW was applied to reduce selection bias, but residual confounding from unmeasured variables (e.g., lesion size, geographic atrophy) cannot be excluded.","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04710-y","tag_type":"warning","value":"The full text provided is primarily a supplementary table; some methodological details (e.g., single vs. multi-centre, exact loading protocol per arm) are not fully verifiable from the available text.","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04710-y","tag_type":"warning","value":"The loading regimens differed between faricimab and aflibercept arms, which may confound both efficacy and treatment burden comparisons — the authors acknowledge this limitation.","value_numeric":null}],"summaries":{"what_studied":"Treatment-naïve nAMD patients (age ≥50) initiating faricimab vs. aflibercept 2 mg under a treat-and-extend regimen (March–September 2024) were compared over 1 year; primary outcomes were BCVA change post-loading and at 1 year, with secondary outcomes including fluid resolution and treatment burden.","key_result":"Faricimab showed greater BCVA improvement at 1 year (adjusted mean difference −0.073 logMAR; 95% CI −0.128 to −0.018; P=0.011), higher SRF resolution rates (OR 2.446; P=0.047), fewer post-loading injections (median 3 vs. 4; P<0.001), and lower therapy switching (7.9% vs. 25.6%; P=0.003).","limitations":"- Non-randomised, retrospective design with potential unmeasured confounding despite IPTW adjustment.\n- Different loading regimens between arms may have introduced differential early treatment exposure.\n- Single-centre or limited follow-up cohort (n=172); generalisability unclear.","practice_takeaway":"In treatment-naïve nAMD, faricimab may offer modest but statistically significant visual and anatomic advantages over aflibercept 2 mg with fewer maintenance injections needed — but the non-randomised design limits causal conclusions. Clinicians should weigh these real-world signals alongside randomised trial data when selecting initial therapy."}},{"doi":"10.1038/s41433-026-04486-1","pmid":"42162248","title":"Infographic: Efficacy and Safety of HighDdose Intravitreal Aflibercept 8 mg in Patients with Treatment-Naïve Neovascular Age-Related Macular Degeneration: Week 96 Results from the Phase 3 PULSAR Trial","journal_title":"Eye","journal_issn":"0950-222X","published_at":"2026-05-20T00:00:00.000Z","url":"https://doi.org/10.1038/s41433-026-04486-1","source_score":11,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-30T13:22:43.943Z","updated_at":"2026-05-30T13:22:43.943Z","tags":[{"paper_doi":"10.1038/s41433-026-04486-1","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04486-1","tag_type":"brand","value":"Eylea HD","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04486-1","tag_type":"category","value":"Ophthalmology","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04486-1","tag_type":"condition","value":"Neovascular Age-Related Macular Degeneration","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04486-1","tag_type":"generic","value":"aflibercept","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04486-1","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04486-1","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04486-1","tag_type":"modality","value":"Anti-VEGF","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04486-1","tag_type":"study_design","value":"Phase 3 Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04486-1","tag_type":"warning","value":"DOI domain '10.1038/s41433-026-04486-1' uses a future year suffix (2026); publication date appears consistent with today's date but the DOI format is unusual — verify when the full paper is indexed.","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04486-1","tag_type":"warning","value":"Sample size was not reported in the available source text and could not be tagged.","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04486-1","tag_type":"warning","value":"Sex distribution of the study population is not stated in the available source text.","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04486-1","tag_type":"warning","value":"Source text is an infographic abstract only — no numerical efficacy or safety data are present, so key results could not be populated with specific figures.","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04486-1","tag_type":"warning","value":"The comparator arm (e.g., aflibercept 2 mg or other agent) is not specified in the available source text.","value_numeric":null}],"summaries":{"practice_takeaway":"High-dose aflibercept 8 mg is being evaluated as an extended-interval treatment option for treatment-naïve nAMD; clinicians should seek the full PULSAR trial publication for specific efficacy and safety figures before changing practice.","what_studied":"The PULSAR Phase 3 trial evaluated the efficacy and safety of high-dose intravitreal aflibercept 8 mg versus a comparator in treatment-naïve patients with neovascular age-related macular degeneration (nAMD) over 96 weeks.","key_result":"This is an infographic summarizing Week 96 results from the PULSAR trial; specific numerical outcomes (e.g., visual acuity changes, anatomical outcomes) are not provided in the source text beyond the trial identifier and timeframe.","limitations":"Source provided is an infographic abstract only — detailed methodology, full outcome data, subgroup analyses, and adverse event rates are not extractable from the available text."}},{"doi":"10.1038/s41433-026-04564-4","pmid":"42156919","title":"Infographic: Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, Phase 3 trial","journal_title":"Eye","journal_issn":"0950-222X","published_at":"2026-05-19T00:00:00.000Z","url":"https://doi.org/10.1038/s41433-026-04564-4","source_score":3,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-21T13:21:02.444Z","updated_at":"2026-05-21T13:21:02.444Z","tags":[{"paper_doi":"10.1038/s41433-026-04564-4","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04564-4","tag_type":"brand","value":"Eylea","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04564-4","tag_type":"category","value":"Ophthalmology","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04564-4","tag_type":"condition","value":"Neovascular Age-Related Macular Degeneration","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04564-4","tag_type":"generic","value":"aflibercept","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04564-4","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04564-4","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04564-4","tag_type":"modality","value":"Anti-VEGF","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04564-4","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04564-4","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04564-4","tag_type":"warning","value":"Brand tag 'Eylea' is used for aflibercept; the 8 mg formulation (Eylea HD) may be a distinct branded product — clinicians should verify the specific product labeling applicable in their region.","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04564-4","tag_type":"warning","value":"Sample size could not be confirmed from the provided source and has been omitted.","value_numeric":null},{"paper_doi":"10.1038/s41433-026-04564-4","tag_type":"warning","value":"This paper is an infographic format, not a full manuscript — granular data (e.g., exact BCVA change values, safety event rates, sample size) are not extractable from the provided metadata alone.","value_numeric":null}],"summaries":{"what_studied":"This Phase 3 randomised, double-masked, non-inferiority trial (PULSAR) evaluated intravitreal aflibercept 8 mg dosed at extended intervals (every 12 or 16 weeks) versus aflibercept 2 mg every 8 weeks in adults with neovascular age-related macular degeneration (nAMD), reporting outcomes at 48 weeks.","key_result":"At 48 weeks, aflibercept 8 mg dosed every 12 or 16 weeks was non-inferior to aflibercept 2 mg every 8 weeks for best-corrected visual acuity gains, supporting extended dosing intervals with the higher-dose formulation.","limitations":"This paper is presented as an infographic, which means full study data, subgroup analyses, and safety details may not be comprehensively reported. Non-inferiority trial design limits ability to detect superiority claims beyond the pre-specified margin.","practice_takeaway":"Aflibercept 8 mg may allow clinicians to extend treatment intervals to every 12–16 weeks in nAMD patients without sacrificing visual acuity outcomes compared to standard 2 mg dosing every 8 weeks. This could meaningfully reduce treatment burden for patients and practices."}},{"doi":"10.1016/j.ophtha.2026.04.031","pmid":null,"title":"En Breve","journal_title":"Ophthalmology","journal_issn":"0161-6420","published_at":"2026-05-11T00:00:00.000Z","url":"https://doi.org/10.1016/j.ophtha.2026.04.031","source_score":2,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":false,"crossref":true,"unpaywall":true},"created_at":"2026-05-20T13:23:24.201Z","updated_at":"2026-05-20T13:23:24.201Z","tags":[{"paper_doi":"10.1016/j.ophtha.2026.04.031","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.04.031","tag_type":"brand","value":"Iluvien","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.04.031","tag_type":"category","value":"Ophthalmology","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.04.031","tag_type":"condition","value":"Age-Related Macular Degeneration","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.04.031","tag_type":"condition","value":"Cataract","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.04.031","tag_type":"condition","value":"Diabetes Mellitus","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.04.031","tag_type":"condition","value":"Diabetic Macular Edema","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.04.031","tag_type":"condition","value":"Diabetic Retinopathy","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.04.031","tag_type":"generic","value":"aflibercept","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.04.031","tag_type":"generic","value":"fluocinolone acetonide","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.04.031","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.04.031","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.04.031","tag_type":"modality","value":"Anti-VEGF Therapy","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.04.031","tag_type":"modality","value":"Artificial Intelligence","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.04.031","tag_type":"modality","value":"Corticosteroid Implant","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.04.031","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.04.031","tag_type":"study_design","value":"Summary / Overview of Multiple Studies","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.04.031","tag_type":"warning","value":"Brand name 'Iluvien' inferred for fluocinolone acetonide 0.19 mg intravitreal implant; not explicitly stated in the text.","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.04.031","tag_type":"warning","value":"Level of evidence assigned as '3' reflects the mix of designs across summarized studies (retrospective series, phase IV RCT, retrospective cohort, Delphi consensus); the RCT alone would rate higher.","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.04.031","tag_type":"warning","value":"Sample size tag reflects the largest single study (DR/mortality, n=524,687); other studies have much smaller cohorts.","value_numeric":null},{"paper_doi":"10.1016/j.ophtha.2026.04.031","tag_type":"warning","value":"This is a Spanish-language summary article ('En Breve') covering four separate linked studies; individual study details (page numbers, full datasets) are not available in this publisher page text.","value_numeric":null}],"summaries":{"what_studied":"This is a summary article ('En Breve') covering four studies published in the same issue of *Ophthalmology*: (1) intravitreal anti-VEGF injections and cataract risk (n=603), (2) fluocinolone acetonide implant vs. aflibercept for diabetic macular edema (n=306, phase IV RCT), (3) baseline diabetic retinopathy severity and mortality risk (n=524,687), and (4) a Delphi consensus on AI reference standards for age-related macular degeneration detection.","key_result":"- **Anti-VEGF & cataracts**: 10-year cumulative cataract surgery incidence was 40.7% in injected eyes vs. 7.2% in contralateral eyes; higher injection burden → higher risk.\n- **FAc implant (NEW DAY trial)**: Primary endpoint not met, but FAc reduced total intravitreal injections by ~50% vs. aflibercept monotherapy with similar visual/anatomic outcomes.\n- **DR severity & mortality**: 7.0% of 524,687 DM patients died over ~5 years; proliferative DR carried the highest mortality risk vs. DM without DR.\n- **AMD AI standard**: Beckman Classification established as the preferred Level 1 reference standard; volumetric OCT recommended as adjunct.","limitations":"- Anti-VEGF/cataract study: retrospective, single tertiary center, lens opacity grading only available at time of surgery, no standardized treatment protocol.\n- NEW DAY trial: primary endpoint not met; no cost-effectiveness analysis; IOP monitoring required with FAc.\n- DR/mortality study: findings may not generalize beyond US tertiary care systems; incomplete data on non-medical factors.\n- AMD Delphi: small expert panel (n=13); Beckman Classification may not be globally applicable.","practice_takeaway":"Clinicians giving repeated intravitreal anti-VEGF injections should counsel patients about a substantially elevated long-term cataract risk (~40% at 10 years). The FAc implant may be a viable baseline option for DME patients where reducing injection burden is a priority, but IOP monitoring is essential."}},{"doi":"10.1001/jamaophthalmol.2026.0460","pmid":"41885869","title":"Peri-Event Intravitreal Anti-VEGF and Systemic Outcomes After Stroke or Myocardial Infarction","journal_title":"JAMA Ophthalmology","journal_issn":"2168-6165","published_at":"2026-03-26T00:00:00.000Z","url":"https://pubmed.ncbi.nlm.nih.gov/41885869/","source_score":15,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-24T13:23:03.271Z","updated_at":"2026-05-24T13:23:03.271Z","tags":[{"paper_doi":"10.1001/jamaophthalmol.2026.0460","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.0460","tag_type":"brand","value":"Avastin","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.0460","tag_type":"brand","value":"Eylea","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.0460","tag_type":"brand","value":"Lucentis","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.0460","tag_type":"category","value":"Ophthalmology","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.0460","tag_type":"condition","value":"Myocardial Infarction","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.0460","tag_type":"condition","value":"Retinal Disease","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.0460","tag_type":"condition","value":"Stroke","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.0460","tag_type":"generic","value":"aflibercept","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.0460","tag_type":"generic","value":"bevacizumab","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.0460","tag_type":"generic","value":"ranibizumab","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.0460","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.0460","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.0460","tag_type":"modality","value":"Anti-VEGF Therapy","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.0460","tag_type":"sample_size","value":"n=11454","value_numeric":11454},{"paper_doi":"10.1001/jamaophthalmol.2026.0460","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.0460","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.0460","tag_type":"warning","value":"Sample size before PSM was 6,073 (stroke) and 5,381 (MI), but matched pairs were substantially smaller (1,526 and 1,523); the pre-PSM total of ~11,454 is used for the sample_size tag as the overall study population.","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.0460","tag_type":"warning","value":"The apparent protective association (lower mortality in peri-event anti-VEGF group) is almost certainly driven by healthy-user bias — patients stable enough to receive injections around a CVE are likely healthier at baseline despite PSM. The study should not be interpreted as evidence that anti-VEGF therapy is cardioprotective.","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.0460","tag_type":"warning","value":"The study window for 'peri-event' exposure spans 14 days pre-CVE to 6 weeks post-CVE, which is a broad and clinically heterogeneous window; subgroup timing analyses are exploratory.","value_numeric":null}],"summaries":{"what_studied":"This retrospective cohort study used TriNetX EHR data (2005–2025) to evaluate whether intravitreal anti-VEGF injections given in the peri-event window (14 days before to 6 weeks after) of stroke or MI were associated with worse mortality, neurologic deficits, or heart failure, compared to patients with no peri-event anti-VEGF. Propensity score matching produced 1,526 stroke pairs and 1,523 MI pairs.","key_result":"Peri-event anti-VEGF was **not** associated with harm. It was linked to **lower** all-cause mortality at 3 months (stroke: RR 0.39, 95% CI 0.29–0.53; MI: RR 0.34, 95% CI 0.26–0.43) and 1 year (stroke: RR 0.52; MI: RR 0.58), as well as fewer neurologic deficits (3-month RR 0.64) and less heart failure at 3 months (RR 0.65). No differences were found across aflibercept, bevacizumab, or ranibizumab.","limitations":"- Retrospective EHR design limits causal inference; residual confounding is possible despite PSM.\n- The apparent protective association likely reflects **healthy-user bias** — patients well enough to receive injections peri-event may be inherently lower-risk.\n- The study cannot determine the optimal timing for resuming therapy after CVE.","practice_takeaway":"Continuing intravitreal anti-VEGF therapy around the time of stroke or MI does not appear to increase mortality or major morbidity, and outcomes were similar across all three commonly used agents. Clinicians can consider maintaining anti-VEGF treatment without mandatory modification during the peri-CVE period, though shared decision-making based on individual clinical status remains essential."}},{"doi":"10.1001/jamaophthalmol.2025.5098","pmid":"41411005","title":"Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy","journal_title":"JAMA Ophthalmology","journal_issn":"2168-6165","published_at":"2025-12-18T00:00:00.000Z","url":"https://doi.org/10.1001/jamaophthalmol.2025.5098","source_score":21,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-12-19","doi":"10.1001/jamaophthalmol.2025.5098","days":"30","issn":"2168-6165","rank":"10","field":"Clinical Medicine","score":"21","category":"Ophthalmology","categories":["Ophthalmology"],"_categories":["Ophthalmology"]},"pubmed":{"doi":"10.1001/jamaophthalmol.2025.5098","title":"Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy: Post Hoc Analysis of the PULSAR Randomized Clinical Trial.","journal":"JAMA ophthalmology","methods":"","results":"$30","abstract":"$31","keywords":[],"pubmed_id":"41411005","conclusions":"","publication_date":"2025-12-18T00:00:00"},"crossref":{"DOI":"10.1001/jamaophthalmol.2025.5098","URL":"https://doi.org/10.1001/jamaophthalmol.2025.5098","ISSN":["2168-6165"],"link":[{"URL":"https://jamanetwork.com/journals/jamaophthalmology/articlepdf/2842906/jamaophthalmology_lee_2025_oi_250078_1765408778.1565.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy"],"author":[{"given":"Won Ki","family":"Lee","sequence":"first","affiliation":[{"name":"Nune Eye Hospital, Seoul, Republic of Korea"}]},{"given":"Tien Y.","family":"Wong","sequence":"additional","affiliation":[{"name":"Tsinghua Medicine, School of Clinical Medicine, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China"},{"name":"Singapore Eye Research Institute, Singapore National Eye Centre, Singapore"}]},{"given":"Shih-Jen","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Taipei Veterans General Hospital, National Yang Ming Chiao Tung University, Taipei, Taiwan"}]},{"given":"Xiaodong","family":"Sun","sequence":"additional","affiliation":[{"name":"Shanghai General Hospital, Shanghai, China"}]},{"given":"Chui Ming Gemmy","family":"Cheung","sequence":"additional","affiliation":[{"name":"Singapore Eye Research Institute, Singapore National Eye Centre, Singapore"},{"name":"Duke-NUS Medical School, National University of Singapore, Singapore"}]},{"given":"Rufino","family":"Silva","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Coimbra, Coimbra, Portugal"},{"name":"Ophthalmology Department, Unidade Local de Saúde de Coimbra, Coimbra, Portugal"},{"name":"Association for Innovation and Biomedical Research on Light and Image (AIBILI), Coimbra, Portugal"},{"name":"Clinical and Academic Centre of Coimbra, Coimbra, Portugal"}]},{"given":"Federico","family":"Ricci","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, Tor Vergata University, Roma, Italy"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Bayer Consumer Care AG, Basel, Switzerland"}]},{"given":"Tobias","family":"Machewitz","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany"}]},{"given":"Andrea","family":"Schulze","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany"}]},{"given":"Ursula M.","family":"Schmidt-Ott","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany"}]},{"given":"Min","family":"Zhao","sequence":"additional","affiliation":[{"name":"Bayer Healthcare Co Ltd, Beijing, China"}]},{"given":"Zoran","family":"Hasanbasic","sequence":"additional","affiliation":[{"name":"Bayer Consumer Care AG, Basel, Switzerland"}]},{"given":"Sergio","family":"Leal","sequence":"additional","affiliation":[{"name":"Bayer Consumer Care AG, Basel, Switzerland"}]},{"given":"Tomohira","family":"Iida","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Tokyo Women’s Medical University, Tokyo, Japan"},{"name":"Current affiliation: Department of Ophthalmology, Ageo Central General Hospital, Saitama, Japan"}]},{"given":null,"family":null,"sequence":"additional","affiliation":[]},{"given":"Patricio","family":"Schlottmann","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Tamara","family":"Zompa","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Arturo","family":"Alezzandrini","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Andrew","family":"Chang","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Jennifer","family":"Arnold","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Samantha","family":"Fraser-Bell","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Alan","family":"Luckie","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Nitin","family":"Verma","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Yosuf","family":"El-Shabrawi","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Peter","family":"Reinelt","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Oliver","family":"Findl","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Anton","family":"Haas","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Matthias","family":"Bolz","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Veselin","family":"Daskalov","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Daniela","family":"Mitova","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Hristina","family":"Blagoeva","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Hristina","family":"Grupcheva","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Aleksandar","family":"Oscar","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Iva","family":"Petkova","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Andrei","family":"Andreev","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Thomas","family":"Sheidow","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Keyvan","family":"Koushan","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Louis-Pierre","family":"Gauvin","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Xiaodong","family":"Sun","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Mingchang 明昌","family":"Zhang 张","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Ke 珂","family":"Fan 范","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Xueyi 雪艺","family":"Chen 陈","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Mei","family":"Han","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Hong","family":"Dai","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Jun 骏","family":"Xiao 肖","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Wenhui 文慧","family":"Yang杨","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Xufang 旭芳","family":"Sun 孙","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Xiaoling 晓玲","family":"Liu 刘","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Shaoping 少平","family":"Ha 哈","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Jing Lin 静琳","family":"Zhang 张","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Qiong 琼","family":"Zhou 周","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Xuguang 旭光","family":"Sun 孙","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Xiaofeng晓峰","family":"Li李","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Yalin 雅琳","family":"He 贺","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Ling 玲","family":"Xu 徐","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Miaoqin 苗琴","family":"Wu 吴","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Jianping 剑萍","family":"Tong 童","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Jian 健","family":"Guo 郭","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Yi 一","family":"Wang 王","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Wenbin","family":"Wei","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Mingwei 明威","family":"Zhao 赵","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Xiaorong","family":"Li","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Cheng 澄","family":"Pei 裴","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Liming 黎明","family":"Tao 陶","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Suyan 甦雁","family":"Li 李","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Lifei 莉菲","family":"Wang 王","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Yanlong 燕龙","family":"Bi 毕","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Xu 旭","family":"Qiu 邱","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Qian 骞","family":"Ren 任","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Jan","family":"Ernest","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Jan","family":"Nemcansky","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Jan","family":"Studnicka","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Miroslav","family":"Veith","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Jan","family":"Hamouz","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Martin","family":"Choleva","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Hana","family":"Fidranska","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Katrin","family":"Hannus","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Kuldar","family":"Kaljurand","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Eric","family":"Souied","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Ramin","family":"Tadayoni","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"François","family":"Devin","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Hessam","family":"Razavi","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Marina","family":"Ramazashvili","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"George","family":"Chichua","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Mikheil","family":"Omiadze","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Jakob","family":"Jikia","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"György","family":"Bátor","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Ágnes","family":"Kerényi","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"András","family":"Seres","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"András","family":"Papp","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Edit","family":"Toth-Molnar","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Attila","family":"Vajas","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Balázs","family":"Varsányi","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Gábor","family":"Vogt","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Tibor","family":"Milibák","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Norbert","family":"Czumbel","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Elad","family":"Moisseiev","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Eva","family":"Platner","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Shiri","family":"Shulman","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Nurit","family":"Mathalone","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Yoreh","family":"Barak","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Haia","family":"Morori-Kats","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Tareq","family":"Jaouni","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Francesco","family":"Bandello","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Federico","family":"Ricci","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Monica","family":"Varano","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Carlo","family":"Cagini","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Enrico","family":"Peiretti","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Angelo Maria","family":"Minnella","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Giovanni","family":"Staurenghi","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Akiko 明子","family":"Miki 三木","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Hideyasu 英泰","family":"Oh 王","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Ken 研","family":"Hayashi 林","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Tatsuya 竜也","family":"Fujisaki 藤﨑","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Tsutomu 力","family":"Yasukawa 安川","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Tetsuju 鉄樹","family":"Sekiryu 石龍","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Tetsuo 哲生","family":"Ueda 上田","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Yuki 祐基","family":"Morizane 森實","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Hideki 英貴","family":"Koizumi 古泉","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Shigeo 茂生","family":"Yoshida 吉田","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Hisashi 央","family":"Matsubara 松原","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Takeshi 剛","family":"Iwase 岩瀬","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Yasuo","family":"Ito","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Jun 潤","family":"Takeuchi 武内","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Kanji 寛二","family":"Takahashi 髙橋","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Yosuke 陽介","family":"Harada 原田","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Kazuhiro","family":"Kimura","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Toru 徹","family":"Noda 野田","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Daisuke 大輔","family":"Takemoto 竹本","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Kazuhiko 和彦","family":"Dannoue 檀之上","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Yoshinori 佳典","family":"Mitamura 三田村","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Kenichi 賢一","family":"Kimoto 木許","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Genichiro 源一郎","family":"Kishino 木住野","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Ryo 亮","family":"Obata 小畑","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Yoichi 庸一","family":"Sakurada 櫻田","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Toshinori 敏規","family":"Murata 村田","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Tetsuya哲哉","family":"Nishimura西村","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Ai 愛","family":"Yoneda 米田","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Hiroshi 洋","family":"Sasaki 佐々木","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Hiroshi 博司","family":"Otake 大竹","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Shunji 俊次","family":"Kusaka 日下","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Kyoko 京子","family":"Fujita 藤田","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Kiyoshi 清","family":"Ishii 石井","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Yasuhiro","family":"Ikeda","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Yoko 洋子","family":"Ozawa 小澤","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Hajime","family":"Shinoda","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Kimimasa 公正","family":"Muranaka 村中","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Ken 顕","family":"Ogino 荻野","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Kiyoshi","family":"Suzuma","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Toshio 俊雄","family":"Okanouchi 岡野内","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Hideo 英雄","family":"Akiyama 秋山","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Namie 奈美江","family":"Kobayashi 小林","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Tomohiro 知弘","family":"Iida 飯田","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Katsuhiro 勝弘","family":"Nishi 西","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Hiroki 宏樹","family":"Tanaka 田中","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Hiroko 寛子","family":"Imaizumi 今泉","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Jiro 二郎","family":"Kogo 向後","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Kanako","family":"Yasuda","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Tomoko 友子","family":"Noda 野田","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Iksoo 익수","family":"Byon 변","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Young Hee","family":"Yoon","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Se Woong","family":"Kang","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Eun Kyoung 경","family":"Lee 이","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Se Joon 세준","family":"Woo 우","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Mihyun","family":"Choi","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Woong 웅","family":"Kim Hyun","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Indars","family":"Lacis","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Guna","family":"Laganovska","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Kristine","family":"Baumane","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Jurate","family":"Balciuniene","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Andrius","family":"Cimbalas","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Jurgita","family":"Kazlauskaite","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Rufino","family":"Martins da Silva","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Carlos","family":"Neves","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Miguel","family":"Lume","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Luis","family":"Silva","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Joao","family":"Figueira","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Maria","family":"Budzinskaya","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Boris","family":"Malyugin","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Miroslav","family":"Stamenkovic","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Dijana","family":"Risimic","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Sinisa","family":"Babovic","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Caroline","family":"Chee","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Chui Ming Gemmy","family":"Cheung","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Marek","family":"Kacerik","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Petr","family":"Kolar","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Blandina","family":"Lipkova","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Gabriela","family":"Pavlovicova","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Maria","family":"Hurcikova","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Laura","family":"Sararols Ramsay","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Jose María","family":"Ruiz Moreno","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"José Ignacio","family":"Vela Segarra","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Alfredo Manuel","family":"Adán Civera","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Miguel","family":"González Andrades","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Luis Emilio","family":"Pablo Julvez","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Enrique","family":"Cervera Taulet","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"María Isabel","family":"Fernández Rodríguez","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Patricia","family":"Udaondo Mirete","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Matthias","family":"Becker","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Aude","family":"Ambresin","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Justus","family":"Garweg","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Wei-Chi 為吉","family":"Wu 吳","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Andrii","family":"Korol","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Iryna","family":"Bezkorovayna","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Tetiana","family":"Shyshkina","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Viacheslav","family":"Povkh","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Nauman","family":"Chaudhry","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Jeffrey","family":"Heier","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"John","family":"Wells","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Michael","family":"Singer","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Philip","family":"Ferrone","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Glenn","family":"Stoller","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Kenneth","family":"Graham","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Harold","family":"Wheatley","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Patrick","family":"Williams","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Michael","family":"Lee","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Eric","family":"Suan","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Judy","family":"Liu","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Patrick","family":"Higgins","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"David","family":"Eichenbaum","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Ghassan","family":"Ghorayeb","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Robert","family":"Wirthlin","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Ramin","family":"Schadlu","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Benjamin","family":"Thomas","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Payam","family":"Amini","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Calvin","family":"Mein","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Sunir","family":"Garg","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"David","family":"Brown","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Steven","family":"Charles","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Charles","family":"Wykoff","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Robert","family":"Mittra","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Nikolas","family":"London","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Veeral","family":"Sheth","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Matthew","family":"Cunningham","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Nicholas","family":"Farber","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Michael","family":"Parrott","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Eduardo","family":"Uchiyama","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Edward","family":"Cherney","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"John","family":"Pitcher","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Prema","family":"Abraham","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Erik","family":"Kruger","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"James","family":"Palmer","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Daniel Virgil","family":"Alfaro","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Wilfredo","family":"Lara","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Sugat","family":"Patel","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Sarah","family":"Read","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Brian","family":"Kim","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Aaron","family":"Weinberg","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Vrinda","family":"Hershberger","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"David","family":"Almeida","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"James","family":"Dooner","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"John","family":"Carlson","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Mihai","family":"Mititelu","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Rajiv","family":"Shah","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"William","family":"Freeman","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Sunil","family":"Gupta","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Ashkan","family":"Pirouz","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Robert","family":"Feldman","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Scott","family":"McClintic","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Kapil","family":"Sampat","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Ramin","family":"Sarrafizadeh","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Jared","family":"Nielsen","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]},{"given":"Carl","family":"Danzig","sequence":"additional","affiliation":[{"name":"for the PULSAR Study Investigators"}]}],"issued":{"date-parts":[[2025,12,18]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":null,"created":{"date-time":"2025-12-18T16:00:27Z","timestamp":1766073627000,"date-parts":[[2025,12,18]]},"indexed":{"date-time":"2025-12-18T16:04:50Z","timestamp":1766073890275,"date-parts":[[2025,12,18]]},"subject":[],"abstract":"$32","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2842906"}},"subtitle":["Post Hoc Analysis of the PULSAR Randomized Clinical Trial"],"deposited":{"date-time":"2025-12-18T16:00:29Z","timestamp":1766073629000,"date-parts":[[2025,12,18]]},"issn-type":[{"type":"print","value":"2168-6165"}],"published":{"date-parts":[[2025,12,18]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1097/01.APO.0000656992.00746.48","key":"eoi250078r1","year":"2020","issue":"3","author":"Chaikitmongkol","volume":"9","first-page":"260","unstructured":null,"article-title":"Latest developments in polypoidal choroidal vasculopathy: epidemiology, etiology, diagnosis, and treatment.","journal-title":"Asia Pac J Ophthalmol (Phila)","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ophtha.2020.08.006","key":"eoi250078r2","year":"2021","issue":"3","author":"Cheung","volume":"128","first-page":"443","unstructured":null,"article-title":"Polypoidal choroidal vasculopathy: consensus nomenclature and non–indocyanine green angiograph diagnostic criteria from the Asia-Pacific Ocular Imaging Society PCV Workgroup.","journal-title":"Ophthalmology","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ophtha.2017.11.019","key":"eoi250078r3","year":"2018","issue":"5","author":"Cheung","volume":"125","first-page":"708","unstructured":null,"article-title":"Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management.","journal-title":"Ophthalmology","doi-asserted-by":"publisher"},{"DOI":"10.3390/diagnostics13101680","key":"eoi250078r4","year":"2023","issue":"10","author":"Zhao","volume":"13","first-page":"1680","unstructured":null,"article-title":"New concepts for the diagnosis of polypoidal choroidal vasculopathy.","journal-title":"Diagnostics (Basel)","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41433-021-01688-7","key":"eoi250078r5","year":"2022","issue":"2","author":"Fenner","volume":"36","first-page":"257","unstructured":null,"article-title":"Evolving treatment paradigms for PCV.","journal-title":"Eye (Lond)","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41598-023-31649-x","key":"eoi250078r6","year":"2023","issue":"1","author":"Fukuyama","volume":"13","first-page":"4800","unstructured":null,"article-title":"Clinical variations of polypoidal choroidal vasculopathy: a cohort study from Japan and the USA.","journal-title":"Sci Rep","doi-asserted-by":"publisher"},{"DOI":"10.2147/OPTH.S385827","key":"eoi250078r7","year":"2023","issue":null,"author":"Sen","volume":"17","first-page":"53","unstructured":null,"article-title":"Polypoidal choroidal vasculopathy: an update on diagnosis and treatment.","journal-title":"Clin Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s40123-024-00952-9","key":"eoi250078r8","year":"2024","issue":"7","author":"Sirks","volume":"13","first-page":"1821","unstructured":null,"article-title":"Perspectives and update on the global shortage of verteporfin (Visudyne).","journal-title":"Ophthalmol Ther","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41433-021-01766-w","key":"eoi250078r9","year":"2022","issue":"6","author":"Ghanchi","volume":"36","first-page":"1154","unstructured":null,"article-title":"An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma.","journal-title":"Eye (Lond)","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(24)00063-1","key":"eoi250078r10","year":"2024","issue":"10432","author":"Lanzetta","volume":"403","first-page":"1141","unstructured":null,"article-title":"Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1001/jama.2025.4347","key":"eoi250078r11","year":"2025","issue":"22","author":"Hopewell","volume":"333","first-page":"1998","unstructured":null,"article-title":"CONSORT 2025 statement: updated guideline for reporting randomized trials.","journal-title":"JAMA","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamaophthalmol.2018.1804","key":"eoi250078r12","year":"2018","issue":"7","author":"Lee","volume":"136","first-page":"786","unstructured":null,"article-title":"Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial.","journal-title":"JAMA Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s12325-022-02162-w","key":"eoi250078r13","year":"2022","issue":"6","author":"Okada","volume":"39","first-page":"2984","unstructured":null,"article-title":"Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in the ALTAIR study: 96-week outcomes in the polypoidal choroidal vasculopathy subgroup.","journal-title":"Adv Ther","doi-asserted-by":"publisher"},{"DOI":null,"key":"eoi250078r14","year":"2018","issue":"4","author":"Morizane-Hosokawa","volume":"72","first-page":"379","unstructured":null,"article-title":"Impact of polyp regression on 2-year outcomes of intravitreal aflibercept injections: a treat-and-extend regimen for polypoidal choroidal vasculopathy.","journal-title":"Acta Med Okayama","doi-asserted-by":null},{"DOI":"10.1007/s40123-023-00850-6","key":"eoi250078r15","year":"2024","issue":"1","author":"Huang","volume":"13","first-page":"385","unstructured":null,"article-title":"Two-year real-world results for aflibercept using the treat-and-extend regimen in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.","journal-title":"Ophthalmol Ther","doi-asserted-by":"publisher"},{"DOI":"10.1136/bjophthalmol-2020-318354","key":"eoi250078r16","year":"2022","issue":"7","author":"Teo","volume":"106","first-page":"987","unstructured":null,"article-title":"Efficacy of a novel personalized aflibercept monotherapy regimen based on polypoidal lesion closure in participants with polypoidal choroidal vasculopathy.","journal-title":"Br J Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.apjo.2025.100144","key":"eoi250078r17","year":"2025","issue":"1","author":"Ruamviboonsuk","volume":"14","first-page":null,"unstructured":null,"article-title":"Consensus and guidelines on diagnosis and management of polypoidal choroidal vasculopathy (PCV) from the Asia-Pacific Vitreo-retina Society (APVRS).","journal-title":"Asia Pac J Ophthalmol (Phila)","doi-asserted-by":"publisher"},{"DOI":"10.1007/s00417-021-05190-4","key":"eoi250078r18","year":"2022","issue":"1","author":"Roh","volume":"260","first-page":"83","unstructured":null,"article-title":"Long-term outcomes of polypoidal choroidal vasculopathy in comparison with typical exudative age-related macular degeneration.","journal-title":"Graefes Arch Clin Exp Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.1111/aos.15149","key":"eoi250078r19","year":"2022","issue":"8","author":"Park","volume":"100","first-page":"e1579","unstructured":null,"article-title":"Comparison of visual outcomes of polypoidal choroidal vasculopathy and typical neovascular age-related macular degeneration-up to 10?years of follow-up.","journal-title":"Acta Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamaophthalmol.2017.4030","key":"eoi250078r20","year":"2017","issue":"11","author":"Koh","volume":"135","first-page":"1206","unstructured":null,"article-title":"Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial.","journal-title":"JAMA Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.1136/bjophthalmol-2021-319090","key":"eoi250078r21","year":"2022","issue":"7","author":"Ogura","volume":"106","first-page":"994","unstructured":null,"article-title":"Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK.","journal-title":"Br J Ophthalmol","doi-asserted-by":"publisher"},{"DOI":null,"key":"eoi250078r22","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"ISRCTN. A study evaluating the effectiveness and safety of faricimab (RO6867461) in participants with polypoidal choroidal vasculopathy. Accessed October 8, 2024. https://www.isrctn.com/ISRCTN69073386","article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Ophthalmology"],"reference-count":22,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,12,18]]},"references-count":22,"short-container-title":["JAMA Ophthalmol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1001/jamaophthalmol.2025.5098","is_oa":false,"title":"Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy","updated":"2025-12-19T02:31:00+00:00","published_date":"2025-12-18","best_oa_location":null}},"created_at":"2026-01-16T11:56:46.634Z","updated_at":"2026-01-17T09:03:27.421Z","tags":[{"paper_doi":"10.1001/jamaophthalmol.2025.5098","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2025.5098","tag_type":"category","value":"Ophthalmology","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2025.5098","tag_type":"condition","value":"Polypoidal Choroidal Vasculopathy","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2025.5098","tag_type":"generic","value":"aflibercept","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2025.5098","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2025.5098","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2025.5098","tag_type":"modality","value":"VEGF Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2025.5098","tag_type":"sample_size","value":"n=139","value_numeric":139},{"paper_doi":"10.1001/jamaophthalmol.2025.5098","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2025.5098","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2025.5098","tag_type":"warning","value":"Post hoc subgroup of an RCT; randomization was not within the PCV subset and analysis was not prespecified.","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2025.5098","tag_type":"warning","value":"Safety outcomes were not detailed in the provided text.","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2025.5098","tag_type":"warning","value":"Study sites were limited to centers performing ICGA in 12 countries, which may not reflect all practice settings.","value_numeric":null}],"summaries":{"what_studied":"A post hoc subgroup analysis of adults with ICGA-confirmed polypoidal choroidal vasculopathy within the PULSAR randomized trial compared aflibercept 8 mg every 12 or 16 weeks vs aflibercept 2 mg every 8 weeks after three monthly doses, measuring BCVA change at week 48.","key_result":"At week 48, LS mean BCVA gains were +9.5 (8 mg q12w), +8.4 (8 mg q16w), and +9.1 letters (2 mg q8w); differences vs 2 mg were 0.40 (95% CI, -4.4 to 5.2) and -0.7 (95% CI, -4.6 to 3.2). Participants received a mean 6.1, 5.1, and 7.0 injections, and 68/78 (87%) on 8 mg maintained ≥12-week dosing; polypoidal lesions were absent in 37%, 47%, and 38% of week-48 completers, respectively.","limitations":"Post hoc subgroup analysis limited to sites performing ICGA in 12 countries. Dosing intervals in 8 mg arms could be shortened after week 16 per disease-activity criteria.","practice_takeaway":"In PCV, aflibercept 8 mg given every 12–16 weeks produced similar 48-week vision gains and lesion outcomes as 2 mg every 8 weeks, with fewer injections and most maintaining ≥12-week intervals. This supports 8 mg aflibercept as an alternative monotherapy for PCV in regimens like those used here."}}],"initialOffset":6,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"generic","value":"aflibercept"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Generics","href":"/hub/tag/generic"},{"name":"aflibercept"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"generic","hub_tag_value":"aflibercept"}}}]]

Papers